Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain - Results of a randomized double-blinded, placebo-controlled trial

Pain

Volumn 103, Issue 3, 2003, Pages 277-283

  Maier, Christoph ^a   Dertwinkel, Roman ^a   Mansourian, Noushin ^a   Hosbach, Ingolf ^a   Schwenkreis, Peter ^a   Senne, Isabel ^a   Skipka, Guido ^a   Zenz, Michael ^a   Tegenthoff, Martin ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Memantine; N Methyl D aspartate receptor antagonist; Phantom limb pain; Placebo controlled randomized trial

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; AGED; ANALGESIC ACTIVITY; ANALYSIS OF VARIANCE; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EXCITATION; FATIGUE; FEMALE; HEADACHE; HUMAN; LIMB PAIN; MALE; MUSCLE CRAMP; NAUSEA; PAIN ASSESSMENT; PHANTOM PAIN; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SIDE EFFECT; VERTIGO;

EID: 0038697564     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(02)00456-6     Document Type: Article

References (47)

1. Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 22:2001;102-110.
2. Bisaga A., Comer S.D., Ward A.S., Popik P., Kleber H.D., Fischman M.W. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology. 157:2001;1-10.
3. Birbaumer N., Karl A., Lutzenberger W., Grodd W., Cohen L.G., Töpfner S., Flor H. Combined transcranial stimulation and neuroelectric source imaging reveal reorganization of somatosensory and motor cortical areas in phantom limb pain. Neuroimage. 5:(Suppl):1997;590.
4. Chaplan S.R., Malmberg A.B., Yaksh T.L. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther. 280:1997;829-838.
5. Cook R.J., Sackett D.L. The number needed to treat: a clinically useful measure of treatment effects. Br Med J. 310:1995;452-454.
6. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci Biobehav Rev. 21:1997;455-468.
7. Dertwinkel R., Heinrichs C., Senne I., Tegenthoff M., Weiss T., Malin J.-P., Zenz M., Maier C. Prevention of severe phantom limb pain by perioperative administration of ketamine - results of a pilot study. Acute Pain. 4:2002;12-16.
8. Dickenson A.H., Sullivan A.F. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacolgy. 26:1987;1235-1238.
9. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. Drugs Res. 41:1991;773-780.
10. Eisenberg E., LaCross S., Strassmann A.M. The clinically tested NMDA receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy. Neurosci Lett. 187:1995;17-20.
11. Eisenberg E., Pud D. Can patients with chronic neuropathic pain can be cured by acute administration of the NMDA receptor antagonist amantadine? Pain. 74:1998;337-339.
12. Eisenberg E., Vos B.P., Strassmann A.M. The NMDA receptor antagonist memantine blocks pain behavior in a rat model of formalin-induced facial pain. Pain. 54:1993;301-305.
13. Flor H., Elbert T., Knecht S., Wienbruch C., Pantev C., Birbaumer N., Larbig W., Taub E. Phantom-limb pain as a perceptual correlate of cortical reorganization following arm amputation. Nature. 375:1995;482-484.
14. Flor H., Elbert T., Muhlnickel W., Pantev C., Wienbruch C., Taub E. Cortical reorganization and phantom phenomena in congenital and traumatic upper-extremity amputees. Exp Brain Res. 119:1998;205-212.
15. Fitzgibbon E.J., Hall P., Schroder C., Seely J., Viola R. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage. 23:2002;165-170.
16. Garraghty P.E., Muja N. NMDA receptors and plasticity in adult primate somatosensory cortex. J Comp Neurol. 367:1996;319-326.
17. Haines D.R., Gaines S.P. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain. 83:1999;283-287.
18. Hewitt D.J. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain. 16:(2 Suppl):2000;S73-S79.
19. Jain K.K. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs. 9:2000;1397-1406.
20. Jackson K., Ashby M., Martin P., Pisasale M., Brumley D., Hayes B. 'Burst' ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage. 22:2001;834-842.
21. Jensen T.S., Krebs B., Nielsen J., Rasmussen P. Immediate and long-term phantom limb pain in amputees: incidence, clinical characteristics and relationship to pre-amputation limp pain. Pain. 21:1985;267-278.
22. Ji R.R., Woolf C.J. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintanence of pathological pain. Neurobiol Dis. 8:2001;1-10.
23. Kannan T.R., Saxena A., Bhatnagar S., Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage. 23:2002;60-65.
24. Kooijman C.M., Dijkstra P.U., Geertzen J.H., Elzinga A., van der Schans C.P. Phantom pain and phantom sensations in upper limb amputees: an epidemiological study. Pain. 87:2000;33-41.
25. Kornhuber J., Bormann J., Hubers M., Rusche K., Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 206:1991;297-300.
26. Kornhuber J., Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett. 195:1995;137-139.
27. Lodder J. Neuroprotection in stroke - analysis of failure, and alternative strategies. Neurosci Res Commun. 26:2000;173-179.
28. Max M.B., Byas-Smith M.G., Gracely R.H., Bennett G.J. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin Neuropharmacol. 18:1995;360-368.
29. McQuay H.J., Moore R.A. An evidence-based resource for pain relief. 1998;Oxford University Press, Oxford. p. 19-31.
30. Nelson K.A., Park K.M., Robinovitz E., Tsigos C., Max M.B. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 48:1997;1212-1218.
31. Neugebauer V., Kornhuber J., Lucke T., Schaible H.G. The clinically available NMDA receptor antagonist memantine is antinociceptive on rat spinal neurones. NeuroReport. 4:1993;1259-1262.
32. Nikolajsen L., Gottrup H., Kristensen A.G., Jensen T.S. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg. 91:2000;960-966.
33. Nikolajsen L., Hansen C.L., Nielsen J., Keller J., Arendt-Nielsen L., Jensen T.S. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain. 67:1996;69-77.
34. Nikolajsen L., Hansen P.O., Jensen T.S. Oral ketamine therapy in the treatment of postamputation stump pain. Acta Anaesthesiol Scand. 41:1997;427-429.
35. Pantev M., Ritter R., Görtelmeyer R. Clinical and behavioural evaluation in long-term-care patients with mild to moderate dementia under memantine treatment. Z Gerontopsychol Psychiatr. 6:1993;103-117.
36. Park K.M., Max M.B., Robinovitz E., Gracely R.H., Bennett G.J. Effects of intravenous ketamine, alfentanil, or placebo on pain, pinprick hyperalgesia, and allodynia produced by intradermal capsaicin in human subjects. Pain. 63:1995;163-172.
37. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology. 38:1999;735-767.
38. Portenoy R.K., Bennett G.J., Katz N.P., Payne R., Price D.D. Enhancing opioid analgesia with NMDA-receptor antagonists: clarifying the clinical importance. A roundtable discussion. J Pain Symptom Manage. 19:(Suppl):2000;S57-S64.
39. Sang C.N. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage. 19:(Suppl. 1):2000;S21-S25.
40. Sang C.N., Booher S., Gilron I., Parada S., Max M.B. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology. 96:2002;1053-1061.
41. Schwenkreis P., Witscher K., Janssen F., Addo A., Dertwinkel R., Zenz M., Malin J.-P., Tegenthoff M. Influence of the NMDA antagonist mementine on human motor cortex excitability. Neurosci Lett. 270:1999;137-140.
42. Stubhaug A., Breivik H., Eide P.K., Kreunen M., Fos A. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand. 41:1997;1124-1132.
43. Suzuki R., Matthews E.A., Dickenson A.H. Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy. Pain. 91:2001;101-109.
44. Treede R.-D., Meyer R.A., Raja S.N., Campbell J.N. Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol. 38:1992;397-421.
45. Warncke T., Stubhaug A., Jørum E. Preinjury treatment with morphine or ketamine inhibits the development of experimentally induced secondary hyperalgesia in man. Pain. 86:1996;293.
46. Woolf C.J., Salter M.W. Neuronal plasticity: increasing the gain in pain. Science. 288:2000;1765-1769.
47. Ziemann U., Chen R., Cohen L.G., Hallett M. Dextromethorphan decreases the excitability of the human motor cortex. Neurology. 51:1998;1320-1324.